RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
Real-time Estimate Cboe BZX  -  11:25 2022-06-28 am EDT
0.9720 USD   +0.21%
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2500 Growth Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2000 Dynamic Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2500 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell

05/24/2022 | 09:26am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 0.39% 145.995 Delayed Quote.-43.20%
RUBIUS THERAPEUTICS, INC. 0.46% 0.9745 Delayed Quote.-90.06%
All news about RUBIUS THERAPEUTICS, INC.
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2500 Growth Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2000 Dynamic Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2500 Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) added to Russell Microcap Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) added to Russell 3000E Value Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) added to Russell Microcap Value Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2000 Growth Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 2000 Index
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell Small Cap Comp Growth Inde..
CI
06/24RUBIUS THERAPEUTICS, INC.(NASDAQGS : RUBY) dropped from Russell 3000 Growth Index
CI
More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -197 M - -
Net cash 2022 74,4 M - -
P/E ratio 2022 -0,48x
Yield 2022 -
Capitalization 87,6 M 87,6 M -
EV / Sales 2022 -
EV / Sales 2023 4,97x
Nbr of Employees 230
Free-Float 93,3%
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 0,97 $
Average target price 7,00 $
Spread / Average Target 622%
EPS Revisions
Managers and Directors
Pablo J. Cagnoni Chief Executive Officer & Director
Jose Carmona Chief Financial Officer
Noubar B. Afeyan Chairman
Spencer Fisk Senior Vice President-Manufacturing
Laurence Turka Chief Scientific Officer & Head-Research
Sector and Competitors
1st jan.Capi. (M$)
RUBIUS THERAPEUTICS, INC.-90.06%87
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-12.75%44 742
BIONTECH SE-48.01%32 574